• Explore /
  • Poster
  • / nextHERIZON: A phase 2 study of HER-Vaxx, a HER2-targeting peptide vaccine, in combination with chemotherapy or pembrolizumab in patients with HER2 metastatic or advanced gastric/gastroesophageal adenocarcinoma that progressed on or after trastuzumab treatment.

nextHERIZON: A phase 2 study of HER-Vaxx, a HER2-targeting peptide vaccine, in combination with chemotherapy or pembrolizumab in patients with HER2 metastatic or advanced gastric/gastroesophageal adenocarcinoma that progressed on or after trastuzumab treatment.

Abstract Poster

Authors

Timothy Price

Timothy Jay Price

Queen Elizabeth Hospital, University of Adelaide, Adelaide, Australia;

Timothy Jay Price , Leslie Mi Ok Chong , Nicholas Ede , Bonnie Nixon , Nimali Withana , Sharon Yavrom , Giovanni Selvaggi , Anthony J. Good

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT05311176

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr TPS481)

DOI

10.1200/JCO.2023.41.4_suppl.TPS481

Abstract #

TPS481

Poster Bd #

N16

Abstract Disclosures

Similar Posters

First Author: Charles S. Fuchs

First Author: Roger B. Cohen

First Author: Charles S. Fuchs

First Author: Daniel V.T. Catenacci